Bachelors Degree in Natural or Agricultural Sciences / Masters Degree in Natural or Agricultural Sciences / BVSc / В. Pharm or Bachelors degree in Biomedical Engineering / Biotechnology.
Ph.D degree in Microbiology / Biochemistry / Biotechnology subject from a recognized University with 5 years R&D/Teaching experience in the relevant subject after Ph.D OR First class MPH / PharmD.
Masters in Analytical Chemistry / Pharmaceutical Sciences / Pharmacology / Chemistry or a related discipline with four years of post-qualification experience in LC-MS / MS-based bioanalysis, preferably DMPK labs in CRO or translational research laboratories.
B.Pharma / D.Pharma with 50% aggregate marks from any recognized institute of India. 0-2 years of experience in the Hospital Pharmacy or Retail Chain of Pharmacy.
Graduate in Life Science (Biology, Botany, Zoology, Microbiology, Genetics, Bioinformatics, Molecular biology etc. with at least 55% marks with 01-year post qualification experience in Bioinformatics.
Post Graduate Degree, including the integrated PG degrees, with five years post qualification experience or PhD + two years post qualification experience.
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company. Our team of 7,500+ colleagues helps make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of 270+ high-quality medicines.
Walk in Drive Looking for candidates with relevant experience in injectable regulated plant as mentioned below
Ipca Laboratories Ltd. has launched its Centre of Excellence (CoE) - a specialized training initiative aimed at providing hands-on industrial exposure to students aspiring to build a career in the pharmaceutical industry.
Emcure is fast-growing Indian pharmaceutical company engaged in developing, manufacturing, and marketing a broad range of pharmaceutical products globally. With a presence in over 70 countries, Emcure's goal is to constantly innovate and deliver affordable & high-quality healthcare solutions to people.
Cipla Limited and its wholly owned subsidiary Cipla USA Inc., announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation from the United States Food and Drug Administration (USFDA). It is the first AB–rated generic therapeutic equivalent of Ventolin® HFA, marketed by GlaxoSmithKline.
Novartis announced that the World Health Organization (WHO) has prequalified Coartem® (artemether-lumefantrine) Baby, the first and only antimalarial developed specifically for newborns and young infants weighing from 2 to 5 kilograms.
Regeneron Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Otarmeni™ (lunsotogene parvec-cwha), the first gene therapy and second new molecular entity approved under the FDA Commissioner’s National Priority Voucher program.